ArticleRheumatology (Oxford, England)2026
Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
objectivesThe impact of the genetic risk for RA on resultant disease phenotype in RA is incompletely understood. Using individual genetic variants associated with RA and a polygenic score (PGS), we hypothesized that those with higher genetic risk for RA would demonstrate a more severe disease course.
methodsWe genotyped participants from the Veterans Affairs RA registry (VARA), a prospective cohort of RA. We evaluated associations between PTPN22 R620W genotype, HLA-DRB1 shared epitope (SE; 0, 1, or 2 copies of a high-risk HLA allele), and a non-HLA PGS with RA disease activity scores and disease characteristics using linear and logistic regression, adjusted for sex, age, and principal components of population structure.
resultsAmong 2557 VARA participants, 50 (2%) were homozygous for PTPN22 R620W, and 1603 (62%) had a PGS greater than the 50th percentile when compared with a reference population. PTPN22 R620W, SE, and the PGS were strongly associated with seropositivity (PGS OR = 1.41, 95% CI 1.26-1.58, P < 0.001). At enrolment, compared with those with no R620W alleles, those with two alleles had higher disease activity [CDAI β = 6.10, 95% CI 1.23-10.97, P = 0.014]; no difference was observed for those with one R620W allele or SE. PGS was not significantly associated with disease activity.
conclusionGenetic variation renders heterogeneous associations with disease activity and phenotype in RA. Individual genetic variants and pathway-specific genetic risk associated with RA may be more informative than the pooled genetic risk in understanding disease phenotype and disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.